Tachyon Receives Funding from CIRM for a Ph 1 Clinical Study of TACH101 in Patients with Advanced Solid Tumors
“Therapy resistance and metastatic dissemination are the main challenges in developing effective cancer treatments. Cancer stem cells and tumor-initiating cells play a significant role in this, and until now, have only been poorly characterized. We have completed extensive preclinical studies to support the clinical advancement of TACH101, and we have shown its ability to reduce the population of tumorigenic cells and potently shrink tumors in cancer models,” said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapeutics. “We are pleased to receive the support of CIRM to advance the first KDM4 inhibitor to enter clinical development.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
